As we have all heard many times on the news, that when a COVID-19 patient gets infected they eventually develop an immune response and generate antibodies to the SARS-CoV-2 virus. However not all antibodies are created equal. Some of these antibodies simply bind to the viral proteins, while others bind in such way that they also have the ability to block the virus from infecting the cells. These antibodies are commonly referred to as neutralizing antibodies. While there are many kits on the market that detect SARS-CoV-2 binding antibodies, here we present performance data for the cPass SARS CoV-2 Neutralization Antibody Test that is FDA EUA authorized and has been shown to be equivalent to live virus tests to detect neutralizing antibodies in clinical studies. We will also share the comparison of the results to other antibody tests and discuss the differences. We will also present data on the quantitative use of the technology that can measure neutralizing antibody levels and it’s potential utility.
1. Brief overview of SARS CoV-2 infection mechanism
2. Description of cPass™ SARS-CoV-2 Neutralization Antibody Test, its advantages and comparative data with live cell neutralization and other serology tests
3. Quantitative protocol for the Neutralization antibody test and its application to samples from recovered SARS CoV-2 patients